A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib [MK0966] in Decreasing the Risk of Prostate Cancer (ViP Study).
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Rofecoxib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck & Co
- 23 Aug 2008 New trial record.